title: Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.
abstract: From October 1983 to October 1986, 39 patients with chronic osteomyelitis (of at least two month's duration) were treated with either pefloxacin (n = 15), ofloxacin (n = 17), or ciprofloxacin (n = 7). The length of treatment ranged from 3 to 6 months; follow-up examinations were performed up until July 1988. The infecting bacterial strains (19 Staphylococcus aureus, 2 Staphylococcus epidermidis, 10 Escherichia coli, 8 Pseudomonas aeruginosa) were all sensitive to the quinolone prescribed. Twenty-nine of the 38 evaluable patients had a satisfactory outcome at follow-up examinations 14 to 48 months after the end of treatment. Fourteen of the 21 patients with gram-positive bacterial infections responded satisfactorily, as did 15 of the 17 patients infected by gram-negative bacteria. Nine cases of failure were observed (2 for pefloxacin, 4 for ofloxacin, 3 for ciprofloxacin). The infecting bacteria were Staphylococcus aureus in six cases (3 on ofloxacin, 3 on ciprofloxacin). The infecting bacteria were Staphylococcus aureus in six cases (3 on ofloxacin, 3 on ciprofloxacin), and Staphylococcus epidermidis (ofloxacin), Escherichia coli (pefloxacin), and Pseudomonas aeruginosa (pefloxacin) in one case each. In all these cases, local conditions (presence of a foreign body in 5 cases, sequestra in 3, and post-radiotherapy necrosis in 1) could have been responsible for treatment failure. Tolerance was good; adverse effects observed in the pefloxacin and ofloxacin groups disappeared after treatment was ended. Bone levels varied but were always superior to the MIC for the pathogen. In view of the satisfactory results, the possibility of oral administration, and the good tolerance, these quinolones should be considered as alternative agents for the treatment of chronic osteomyelitis.
authors.affiliation: Department of Infectious and Tropical Diseases, Archet Hospital, Nice, France.
authors.forename: P
authors.initials: P
authors.lastname: Dellamonica
authors.forename: E
authors.initials: E
authors.lastname: Bernard
authors.forename: H
authors.initials: H
authors.lastname: Etesse
authors.forename: R
authors.initials: R
authors.lastname: Garraffo
authors.forename: H B
authors.initials: HB
authors.lastname: Drugeon
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004926:Escherichia coli; D005260:Female; D006801:Humans; D008297:Male; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010019:Osteomyelitis / Q000188:drug therapy*; D015366:Pefloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011550:Pseudomonas aeruginosa; D013211:Staphylococcus aureus; D013212:Staphylococcus epidermidis
chemical_list: D015366:Pefloxacin; D002939:Ciprofloxacin; D015242:Ofloxacin